MYC inhibition by Omomyc as a therapeutic strategy for (KRAS-mutated) colorectal cancer

被引：0
|
作者：
Kaur, J. [1 ]
Martinez-Martin, S. [2 ]
Foradada, L. [2 ]
Lopez-Estevez, S. [2 ]
Serrano, E. [1 ]
Martin-Fernandez, G. [1 ]
Thabussot, H. [3 ]
Cano, V. Castillo [3 ]
Casacuberta-Serra, S. [4 ]
Zacarias-Fluck, M. F. [1 ]
Grueso, J. [1 ]
Beaulieu, M. E. [5 ]
Whitfield, J. R.
Soucek, L. [1 ,5 ,6 ,7 ]
机构：
[1] Vall dHebron Inst Oncol, Models Canc Therapies Grp, Barcelona, Spain
[2] Peptomyc SL, Biomarkers, Barcelona, Spain
[3] Peptomyc SL, Prot Prod Platform, Barcelona, Spain
[4] Peptomyc SL, Immuno Oncol, Barcelona, Spain
[5] Peptomyc SL, Peptomyc, Barcelona, Spain
[6] Inst Catalana Recerca & Estudis Avancats, Icrea, Barcelona, Spain
[7] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Bellaterra, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
68
引用
收藏
页码：S24 / S24
页数：1
相关论文
共 50 条
  • [31] Realities of KRAS-mutated non-small cell lung cancer
    Min, Young Joo
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2017, 32 (03): : 442 - 442
  • [32] Protein arginine methyltransferase 5 as a therapeutic target for KRAS mutated colorectal cancer
    Shifteh, David
    Sapir, Tzuriel
    Goel, Sanjay
    Maitra, Radhashree
    CANCER RESEARCH, 2020, 80 (16)
  • [33] The Potential Treatment Options and Combination Strategies of KRAS-Mutated Lung Cancer
    Zhao, Xinchao
    Zheng, Yawen
    Wang, Yufeng
    Zhang, Mingyan
    Dong, Zhilin
    Liu, Yanan
    Sun, Meili
    ONCOTARGETS AND THERAPY, 2024, 17 : 1041 - 1057
  • [34] Response to comment on ‘KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer’
    K-L G Spindler
    N Pallisgaard
    R F Andersen
    A Jakobsen
    British Journal of Cancer, 2014, 111 : 2380 - 2380
  • [35] p27kip1 expression and phosphorylation dictate Palbociclib sensitivity in KRAS-mutated colorectal cancer
    Gian Luca Rampioni Vinciguerra
    Alessandra Dall’Acqua
    Ilenia Segatto
    Maria Chiara Mattevi
    Francesca Russo
    Andrea Favero
    Roberto Cirombella
    Giorgia Mungo
    Davide Viotto
    Javad Karimbayli
    Margherita Pesce
    Andrea Vecchione
    Barbara Belletti
    Gustavo Baldassarre
    Cell Death & Disease, 12
  • [36] SK4 oncochannels regulate calcium entry and promote cell migration in KRAS-mutated colorectal cancer
    Ibrahim, Sajida
    Chaigne, Justine
    Dakik, Hassan
    Fourbon, Yann
    Corset, Laetitia
    Lecomte, Thierry
    Raoul, William
    Gueguinou, Maxime
    CELL CALCIUM, 2021, 96
  • [37] Targeting Smurf1 to block PDK1-Akt signaling in KRAS-mutated colorectal cancer
    Peng, Zhiqiang
    Fang, Wei
    Wu, Bo
    He, Ming
    Li, Shaohua
    Wei, Jun
    Hao, Yang
    Jin, Lujia
    Liu, Mingqiu
    Zhang, Xin
    Wei, Yange
    Ge, Yingwei
    Wei, Yinghua
    Qian, Haili
    Zhang, Yangjun
    Jiang, Junyi
    Chang, Zhijie
    Rao, Yu
    Zhang, Xueli
    Cui, Chun-Ping
    Zhang, Lingqiang
    NATURE CHEMICAL BIOLOGY, 2025, 21 (01) : 59 - 70
  • [38] Response to comment on 'KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer'
    Spindler, K-L G.
    Pallisgaard, N.
    Andersen, R. F.
    Jakobsen, A.
    BRITISH JOURNAL OF CANCER, 2014, 111 (12) : 2380 - 2380
  • [39] Management of KRAS-Mutated Non-Small Cell Lung Cancer
    Malhotra, Jyoti
    Nguyen, Danny
    Tan, Tingting
    Semeniuk, George B.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (02) : 67 - 75
  • [40] A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer
    Do, Khanh
    Cao, Liang
    Kang, Zhigang
    Turkbey, Baris
    Lindenberg, Maria L.
    Larkins, Erin
    Holkova, Beata
    Steinberg, Seth M.
    Raffeld, Mark
    Peer, Cody J.
    Figg, William D.
    Eugeni, Michelle
    Jacobs, Paula
    Choyke, Peter
    Wright, John J.
    Doroshow, James H.
    Kummar, Shivaani
    CLINICAL COLORECTAL CANCER, 2015, 14 (03) : 154 - 161
12345